Economic Evaluation of PCV21 Use in Populations with Increasing Serotype 4 Invasive Pneumococcal Disease in the US: An Attributable Fraction Threshold Analysis

Abstract Introduction The 21-valent pneumococcal conjugate vaccine (PCV21) covers 83–88% of IPD in US adults but does not include serotype 4 (ST4), which is covered by previously recommended vaccines (PPSV23, PCV15, PCV20). Recent increases in IPD cases due to ST4 have been observed, particularly am...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Zinan Yi, Kwame Owusu-Edusei, Elmira Flem, Kristen Feemster, Elamin H. Elbasha
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2026-05-01
coleção:	Infectious Diseases and Therapy
Assuntos:	Adult Pneumococcal vaccine Decision analysis Pneumococcal infections
Acesso em linha:	https://doi.org/10.1007/s40121-026-01364-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!